RAM
TARS icon

Riggs Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Riggs Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$272 – 698
2024
Q2 		$272 Hold
10
– – ﹤0.01% 618
2024
Q1 		$364 Buy
+10
New +$294 ﹤0.01% 581

Other funds holding TARS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Riggs Asset Management's TARS Position: Q3 2024 in Review

Riggs Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2024, closing a stake of 10 shares — an estimated $272 sold.

Riggs Asset Management first reported a position in TARS in Q1 2024 and held it in 2 quarters. The position peaked at $364 in Q1 2024. 162 funds tracked by Wall St. Rank hold TARS as of Q3 2024.

  • Riggs Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Riggs Asset Management sold 10 Tarsus Pharmaceuticals shares in Q3 2024, an estimated $272.
  • Riggs Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Riggs Asset Management's Tarsus Pharmaceuticals position peaked at $364 in Q1 2024.
  • 162 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2024.

Based on Riggs Asset Management's 13F filing for Q3 2024, filed 24 Oct 2024.